TScan Therapeutics
IPOEngineering Immunity
Public · Waltham, United States · Founded 2018 · $190.0M raised
- Headquarters
- Waltham, Massachusetts
- Employees
- 51–200
- Founded
- 2018
- Business Model
- B2B
- Website
- ir.tscan.com
- Total Funding
- $190.0M
- Last Round
- $30.0M Corporate RoundDec 2024
- Rounds
- 4
- Type
- Public
About
TScan Therapeutics is a fully integrated clinical-stage biotechnology company developing T cell receptor-engineered T cell (TCR-T) therapies for patients with cancer and autoimmune disorders. Founded in 2018, its lead candidate TSC-101 targets AML and MDS patients undergoing allogeneic transplant, with a Phase 3 trial expected in 2026.
Summary
TScan Therapeutics is a Biotech company based in Waltham, United States, founded in 2018. It has raised $190.0M in total across 4 rounds, most recently a $30.0M Corporate Round round in Dec 2024. Investors include Lynx1 Capital Management, BlackRock and RA Capital Management.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Dec 2024
Sign up to see all 6 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Alphabet-backed biotechnology company researching biology of aging and developing interventions t...